You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 7,011,819


✉ Email this page to a colleague

« Back to Dashboard


Title:Delivery of rizatriptan or zolmitriptan through an inhalation route
Abstract: The present invention relates to the delivery of headache and anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing that are used in inhalation therapy. In a method aspect of the present invention, rizatriptan or zolmitriptan is administered to a patient through an inhalation route. The method comprises: a) heating a composition, comprising rizatriptan or zolmitriptan to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol with less than 5% of the drug degradation products. In a kit aspect of the present invention, a kit for delivering rizatriptan or zolmitriptan through an inhalation route is provided which comprises: a) a thin coating of a rizatriptan or zolmitriptan composition; and, b) a device for dispending said thin coating as a condensation aerosol.
Inventor(s): Hale; Ron L. (Woodside, CA), Rabinowitz; Joshua D. (Mountain View, CA), Solas; Dennis W. (San Francisco, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Palo Alto, CA)
Filing Date:Mar 03, 2004
Application Number:10/792,096
Claims:1. A method of treating headache or migraine in a patient comprising administering a therapeutic amount of a rizatriptan condensation aerosol to the patient by inhalation, wherein the therapeutic amount of a rizatriptan condensation aerosol comprises between 1 mg and 20 mg of rizatriptan delivered in a single inspiration, and wherein the condensation aerosol is formed by heating a thin layer containing rizatriptan, on a solid support, to produce a vapor of rizatriptan, and condensing the vapor to form a condensation aerosol characterized by less than 10% rizatriptan degradation products by weight, and an MMAD of less than 5 microns.

2. A method of treating headache or migraine in a patient comprising administering a therapeutic amount of a zolmitriptan condensation aerosol to the patient by inhalation, wherein the therapeutic amount of a zolmitriptan condensation aerosol comprises between 0.5 mg and 10 mg of zolmitriptan delivered in a single inspiration, and wherein the condensation aerosol is formed by heating a thin layer containing zolmitriptan, on a solid support, to produce a vapor of zolmitriptan, and condensing the vapor to form a condensation aerosol characterized by less than 10% zolmitriptan degradation products by weight, and an MMAD of less than 5 microns.

3. A method of administering a dose form of rizatriptan to a patient comprising administering the dose form to the patient by inhalation, wherein the dose form comprises less than 4 mg of rizatriptan, and wherein the dose form further comprises a condensation aerosol formed by heating a thin layer containing rizatriptan, on a solid support, to produce a vapor of rizatriptan, and condensing the vapor to form a condensation aerosol characterized by less than 10% rizatriptan degradation products by weight, and an MMAD of less than 5 microns.

4. A method of administering a dose form of zolmitriptan to a patient comprising administering the dose form to the patient by inhalation, wherein the dose form comprises less than 1 mg of zolmitriptan, and wherein the dose form further comprises a condensation aerosol formed by heating a thin layer containing zolmitriptan, on a solid support, to produce a vapor of zolmitriptan, and condensing the vapor to form a condensation aerosol characterized by less than 10% zolmitriptan degradation products by weight, and an MMAD of less than 5 microns.

5. A method of administering a rizatriptan condensation aerosol to a patient comprising administering the rizatriptan condensation aerosol to the patient by inhalation, wherein the rizatriptan condensation aerosol is formed by heating a thin layer containing rizatriptan, on a solid support, to produce a vapor of rizatriptan, and condensing the vapor to form a condensation aerosol characterized by less than 5% rizatriptan N-oxide or didehydro rizatriptan by weight, and an MMAD of less than 5 microns.

6. A method of administering a zolmitriptan condensation aerosol to a patient comprising administering the zolmitriptan condensation aerosol to the patient by inhalation, wherein the zolmitriptan condensation aerosol is formed by heating a thin layer containing zolmitriptan, on a solid support, to produce a vapor of zolmitriptan, and condensing the vapor to form a condensation aerosol characterized by less than 5% zolmitriptan N-oxide or didehydro zolmitriptan by weight, and an MMAD of less than 5 microns.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.